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PathogenesisWe previously reported that the Japanese encephalitis virus (JEV) strain Mie/41/2002 has weak
pathogenicity compared with the laboratory strain Beijing-1. To identify the determinants of its growth
nature and pathogenicity, we produced intertypic viruses, rJEV(EB1-M41), rJEV(nEB1-M41) and rJEV(cEB1-
M41), which contained the entire, the N-terminal, and the C-terminal half, respectively, of the Beijing-1 E
region in the Mie/41/2002 background. The growth of rJEV(EB1-M41) in mouse neuroblastoma N18 cells and
virulence in mice were similar to those of Beijing-1. rJEV(nEB1-M41) propagated in N18 cells to the same
extent as did Beijing-1. Furthermore, we produced mutant viruses with single amino acid substitutions in the
N-terminal half of theMie/41/2002 E region. A Ser-123-Argmutation in theMie/41/2002 E protein exhibited
signiﬁcantly increased growth rate in N18 cells and virulence in mice. These results indicate that the position
123 in the E protein is responsible for determining the growth properties and pathogenicity of JEV.
© 2009 Elsevier Inc. All rights reserved.Introduction
Japanese encephalitis (JE) is a disease caused by Japanese
encephalitis virus (JEV), which is transmitted to humans by
mosquitoes. JEV causes serious nervous disorders encephalitis and
meningitis. Approximately 1–3 of every 1000 JEV infections results in
severe disease, and the fatality rate of JE is approximately 30%. Each
year, 30,000–50,000 clinical cases of JE are reported with 10,000
deaths, mainly in China, South-East Asian countries, and India (Tsai,
2000). Most cases of JE occur in South, East, and South-East Asia
(WHO, 1998). In recent decades, JE patients have been reported in
northern area of Australia (Hanna et al., 1996). In Japan, more than
100 cases of JE were reported annually in the 1960s. After the mid-
1960s, the incidence of JE has markedly decreased and less than 10
cases have been reported annually since the early 1990s. However, a
high percentage of naïve pigs seroconvert to JEV every year in most
regions of Japan, suggesting that JEV is still circulating in Japan.
Although the reasons for the decrease in the number of JE cases after
the mid-1960s are unclear, the establishment of a JE vaccination
program, separation of pig farms and residential areas, and changes in
rice farming procedures are likely important contributing factors.
JEV belongs to the genus Flavivirus within the family Flaviviridae
and is now classiﬁed into ﬁve genotypes (genotype I–V) based on the
sequence of its genomic RNA (Uchil and Satchidanandam, 2001;
Solomon et al., 2003). JEV has a single-stranded, positive-sense RNA
genome. The approximately 11-kb genome encodes three structuralane@nih.go.jp (I. Kurane).
ll rights reserved.proteins (C, prM and E) and seven non-structural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B and NS5) in one open reading frame. It
also has non-translated regions (NTRs) in its 5′ and 3′ terminal ends
(Lindenbach and Rice, 2001). The E (envelope) protein is the major
structural protein that constitutes the surface structure of the
ﬂavivirus particles. This protein has a putative receptor-binding
domain and neutralization epitopes and also plays major roles in
determining viral pathogenicity by deﬁning cell tropism and affecting
penetration into susceptible cells (Lindenbach and Rice, 2001; Burke
andMonath, 2001). The crystallographic structure of the E protein of a
ﬂavivirus tick-borne encephalitis virus revealed that the E protein
forms head-to-tail homodimers and consists of three domains;
domain I (central domain), II (dimerization domain), and III
(immunoglobulin-like domain) (Rey et al., 1995).
Various approaches to clarify the molecular basis of JEV virulence
have been made since the early 1990s by comparing the nucleotide
sequences of virus strains with different degrees of virulence
(Nitayaphan et al., 1990; Aihara et al., 1991; Cecilia and Gould,
1991; Hasegawa et al., 1992; Sumiyoshi et al., 1995; Chen et al., 1996;
Ni and Barrett, 1996; Ni and Barrett, 1998; Arroyo et al., 2001; Wu et
al., 2003; Lee et al., 2004; Chambers et al., 2007). Reports have
suggested that some nucleotide substitutions in the E protein may
correlate with the pathogenicity of JEV. A single amino acid
substitution at position 138 (Glu to Lys) in the E protein is associated
with attenuation of the JEV strain; this ﬁnding was demonstrated in a
study using an infectious clone of JEV (Sumiyoshi et al., 1995; Zhao et
al., 2005). It was also shown in a chimera of yellow fever virus and JEV
that a single amino acid substitution at position 279 (Met to Lys)
increases virulence in mice (Monath et al., 2002). On the other hand,
recent reports showed that mutations in the 5′-NTR, C, and prM
Fig. 1. (A) Plaque phenotypes of JEV Mie/41/2002 and Beijing-1 in Vero and porcine
kidney PK15 cells. (B) Growth curves of Mie/41/2002 and Beijing-1 in mosquito C6/36
cells.
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(Mori et al., 2005; Chambers et al., 2007; Kim et al., 2008).
Recently, we have isolated JEV from pigs and characterized the
JEVs prevalent in Japan (Nerome et al., 2007). Of the new isolates,
isolate Mie/41/2002 showed signiﬁcantly weak virulence compared
with that of genotype III strain Beijing-1 (Nerome et al., 2007).
Genetic analysis indicated that there are some differences in the
nucleotide sequence in E region between Mie/41/2002 and Beijing-1,
raising the possibility that the amino acid residues in the E region of
Mie/41/2002 may be related to the difference in virulence between
Mie/41/2002 and Beijing-1. In the present study, we tested whether
the E region of Beijing-1 can enhance the virulence of Mie/41/2002 in
a mouse model by reconstituting three intertypic viruses containing
the full or partial sequences of the E region of Beijing-1 and four
single-missense mutant viruses in the Mie/41/2002 background. We
also compared the growth properties of the viruses in vitro. Finally,
we found a newmolecular determinant for the growth properties and
pathogenicity of JEV in the E protein.
Results
Growth properties of Mie/41/2002 and Beijing-1 in Vero, PK15 and
C6/36 cells
Our previous study showed that the neurovirulence and neuroin-
vasiveness of Mie/41/2002 are signiﬁcantly lower than those of
Beijing-1 in mice (Nerome et al., 2007). This ﬁnding raises the
possibility that Mie/41/2002 may replicate less efﬁciently than
Beijing-1 in cultured cells. To further characterize the nature of
Mie/41/2002 in vitro, we inoculated Vero cells, porcine kidney PK15
cells and mosquito C6/36 cells with these two strains, and the
resulting plaque size and growth kinetics were compared. The plaque
size of Mie/41/2002 was larger than that of Beijing-1 in Vero and
PK15 cells (Fig. 1A and Table 1). Replication of Mie/41/2002 was
faster than that of Beijing-1 in C6/36 cells (Fig. 1B). These results
indicate that the ability of Mie/41/2002 to replicate in Vero, PK15 and
C6/36 cells may be higher than that of Beijing-1 and that the virulence
of JEV in mice is not necessarily correlated with its ability to replicate
in these cell lines.
Growth properties of a intertypic JEV rJEV(EB1-M41) in Vero and
N18 cells
It has been reported that the E protein is associated with the
replication and virulence of JEV. Therefore, we hypothesized that the E
region is involved in the different effects of Mie/41/2002 and Beijing-1.
We compared the amino acid sequences of the E region of these two
strains (Table 2). The identity of the amino acid sequence between
these strains was 98.4%. Eight amino acids (positions 123, 129, 222,
227, 327, 366, 397, and 473) were different between Mie/41/2002
and Beijing-1. To investigate whether the differences in the amino acid
sequences affect the growth properties of the JEV, we produced a
recombinant intertypic JEV strain, rJEV(EB1-M41), which has the
entire E region of Beijing-1 in the backbone of the Mie/41/2002
genome, as described in Materials and Methods. Plaque morphology
and the growth rate of the recombinant virus in Vero cells were
compared with those of Mie/41/2002 and Beijing-1. The plaques
formed by rJEV(EB1-M41) were smaller than those formed by Mie/
41/2002 and similar to those formed by Beijing-1 (Table 1). The
growth kinetics of Mie/41/2002 was clearly faster than those of
Beijing-1, and the kinetics of rJEV(EB1-M41) was between those of
Mie/41/2002 and Beijing-1 (Fig. 2A). These data suggest that the E
region of Beijing-1 is associated with small plaque size and is partially
related to the slower growth rate of Beijing-1 in Vero cells.
Next, we examined the growth properties of the three JEV strains in
mouse neuroblastoma-derived N18 cells. In contrast to the results inVero cells, the growth rate of Beijing-1 was slightly faster than that of
Mie/41/2002, and the steady state level of the number of infectious
particles of Beijing-1was signiﬁcantly higher than that ofMie/41/2002
(Fig. 2B). Furthermore, the growth curve of rJEV(EB1-M41) in N18 cells
was nearly equal to that of Beijing-1. These data suggest that Mie/41/
2002 and Beijing-1 have different cell tropism and that the E region of
Beijing-1 is involved in the nerve cell-tropic nature of the virus.
Comparison of the virulence of Mie/41/2002, Beijing-1, and rJEV
(EB1-M41) in mice
To determine whether the E region of Beijing-1 is related to its
virulence in vivo, mice were infected intraperitoneally with Mie/41/
2002, Beijing-1, and rJEV(EB1-M41) and observed for 3 weeks
(Table 3, experiment 1). We assessed the neuroinvasiveness by
determining the ability of the viruses to replicate in peripheral tissues,
invade the central nerve system, and cause encephalitis. Nine of the
10 mice infected with Beijing-1 had died, whereas 3 of the 10 mice
Table 1
Plaque size of recombinant JEVs in Vero cells.
Strain Mean plaque size
(mm) ±standard errora
P value
(vs. Mie/41/2002)b
P value
(vs. Beijing-1)c
Mie/41/2002 1.83±0.04 – b0.0001⁎
Beijing-1 0.92±0.03 b0.0001⁎ –
rJEV(EB1-M41) 0.98±0.03 b0.0001⁎ 0.12
rJEV(nEB1-M41) 1.03±0.04 b0.0001⁎ 0.03⁎
rJEV(cEB1-M41) 1.78±0.04 0.24 b0.0001⁎
rJEV(E123B1-M41) 1.03 ±0.05 b0.0001⁎ 0.04⁎
rJEV(E129B1-M41) 1.8±0.04 0.31 b0.0001⁎
rJEV(E222B1-M41) 1.85±0.04 0.37 b0.0001⁎
rJEV(E227B1-M41) 1.86±0.03 0.27 b0.0001⁎
a Plaque diameters calculated for 15 plaques.
b P value relative to Mie/41/2002 by Welch's t-test. Asterisks indicate statistical signiﬁcance.
c P value relative to Beijing-1 by Welch's t-test. Asterisks indicate statistical signiﬁcance.
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with rJEV(EB1-M41) had died by 2 weeks after challenge, resembling
the Beijing-1-inoculated group. This result suggests that the E protein
contributes to the difference in virulence observed between the Mie/
41/2002 and Beijing-1 strains in vivo and that there is a correlation
between growth characteristics of JEV in N18 and virulence in vivo.
Effect of four single-missense mutations in E protein on the nature of
Mie/41/2002 in vitro
Our results suggest that one or more of the eight amino acid
sequence variances in the E region are associated with the growth
properties of Mie/41/2002. To deﬁne the amino acid positions
responsible for the virulence and growth properties, we produced
two new intertypic recombinant viruses, rJEV(nEB1-M41) and rJEV
(cEB1-M41), which have the N-terminal half (1–268) and the C-
terminal half (269–500), respectively, of the E region of Beijing-1 in a
Mie/41/2002 background (Table 2). We examined the growth
properties of these viruses in Vero and N18 cells. In Vero cells, the
plaques formed by rJEV(nEB1-M41) were clearly smaller than those
formed by Mie/41/2002 and rJEV(cEB1-M41) but were slightly larger
than those of Beijing-1 (Table 1). The growth kinetics of rJEV(nEB1-
M41) and rJEV(cEB1-M41) in Vero cells were comparable to those of
rJEV(EB1-M41) and Mie/41/2002, respectively (Fig. 3A). The growth
rate of rJEV(nEB1-M41) was equivalent to that of Beijing-1 and rJEV
(EB1-M41) in N18 cells (Fig. 3B). rJEV(cEB1-M41) and Mie/41/2002
showed similar growth rates in N18 cells, although the steady state
level of the number of infectious particles of rJEV(cEB1-M41) was
slightly lower as compared to that ofMie/41/2002. Our results suggest
that the N-terminal half of the E region is responsible for the difference
in the growth properties between Mie/41/2002 and Beijing-1.
To determine the amino acid in the E protein that is responsible for
the Beijing-1-like phenotype, we produced four additional recombi-
nant viruses, rJEV(E123B1-M41), rJEV(E129B1-M41), rJEV(E222B-
M41) and rJEV(E227B1-M41), which each have single-missense
mutations in the nE protein of Mie/41/2002 (Table 2). We examined
the plaque size and growth characteristics of these viruses in vitro. In
Vero cells, the mutant virus rJEV(E123B1-M41) formed smaller
plaques than did Mie/41/2002 but its plaques were slightly larger
than those of Beijing-1 (Table 1). The plaque size was similar than thatTable 2
Difference of amino acid residues in the E region between Mie/41/2002 and Beijing-1.
Amino acid position in the E region nE regiona cE regionb
123 129 222 227 327 366 397 473
Mie/41/2002 S M S S T S H V
Beijing-1 R T A P S A Y I
a From amino acid positions 1–268 in the E region.
b From amino acid positions 269–500 in the E region.of rJEV(nEB1-M41) (Table 1). However, growth kinetics analysis
showed that the Ser-123-Arg (S123R) mutation did not affect the
growth rate of Mie/41/2002 in Vero cells (Fig. 4A). In contrast, rJEV
(E227B1-M41) grew slightly slower than Mie/41/2002 and the other
three missense mutants, although the plaque morphology of rJEV
(E227B1-M41) was similar to that of Mie/41/2002. Our data suggest
that two different amino acid substitutions, S123R and Ser-227-ProFig. 2. Growth curves of Mie/41/2002, Beijing-1, and intertypic recombinant JEV rJEV
(EB1-M41) in Vero cells (A) and in N18 cells (B). Values represent the mean and
standard deviation (SD) for three independent tests.
Table 3
Mouse neuroinvasiveness of recombinant JEVs.
Virus Experiment 1 Experiment 2 Experiment 3
Survivala P valueb Survivala P valueb Survivala P valueb
Mie/41/2002 7/10 – 9/10 – 7/10 –
Beijing-1 1/10 0.012⁎ 0/10 b0.0001⁎ 0/10 b0.0001⁎
rJEV(EB1-M41) 2/10 0.051
rJEV(E123B1-M41) 3/10 0.004⁎ 1/10 0.002⁎
rJEV(E129B1-M41) 9/10 0.97 7/10 0.86
rJEV(E222B1-M41) 9/10 1.00 6/10 0.48
rJEV(E227B1-M41) 7/10 0.27 7/10 0.85
a No. of mice surviving/no. of mice inoculated.
b P value relative to Mie/41/2002 by log-rank (Mantel–Cox) test. Asterisks indicate statistical signiﬁcance.
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growth rate, respectively, in Vero cells.
In N18 cells, rJEV(E123B1-M41) and Beijing-1 had a similar
growth curve; however, the growth kinetics of rJEV(E123B1-M41)
was slightly higher than that of Beijing-1 (Fig. 4B). Mie/41/2002 and
the other three recombinant viruses had similar growth patterns.
These results suggest that only the S123R mutation increases the
growth rate of Mie/41/2002 to the level of Beijing-1 in N18 cells and
that Arg at position 123 in the E protein is a key factor in the nerve
cell-tropic nature of Beijing-1.Fig. 3. Growth curves of Mie/41/2002, Beijing-1, rJEV(EB1-M41), rJEV(nEB1-M41) and
rJEV(cEB1-M41) in Vero cells (A) and N18 cells (B).Effect of missense mutations in E protein on the virulence of
Mie/41/2002 in mice
To determine whether the single-missense mutations in Mie/41/
2002 enhanced the virulence of Mie/41/2002 in vivo, mice were
infected intraperitoneally with Mie/41/2002, Beijing-1, and the four
missense mutant viruses (Table 3, experiments 2 and 3). Only 1 and 3
of the 10 mice infected with Mie/41/2002 had died, whereas all mice
infected with Beijing-1 had died. In rJEV(E123B1-M41)-infected mice,
7 and 9 of the 10 mice had died, while 1 and 3 of the 10 mice infected
with rJEV(E129B1-M41), 1 and 4 of the 10 mice infected with rJEV
(E222B1-M41), and 3 and 3 of the 10mice infectedwith rJEV(E227B1-Fig. 4. Growth curves of Mie/41/2002, Beijing-1, rJEV(E123B1-M41), rJEV(E129B1-
M41), rJEV(E222B1-M41), and rJEV(E227B1-M41) in Vero cells (A) and N18 cells (B).
Values represent the mean and SD for three independent tests.
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was similar to that of Beijing-1 (data not shown). This result suggests
that the S123R mutation signiﬁcantly enhances the virulence of Mie/
41/2002 in vivo, indicating that the amino acid at position 123 in the E
protein is responsible for determining the virulence of JEV in vivo.
Discussion
We previously reported that the JEV Mie/41/2002 strain has
signiﬁcantly weak virulence compared to that of the Beijing-1 strain
(Nerome et al., 2007). In this paper we have attempted to identify the
amino acid in the E protein that is responsible for the growth
properties and pathogenicity of JEV. Our results showed that the
virulence of Mie/41/2002 was increased by an amino acid substitu-
tion at position 123 (S123R). Previous reports have suggested many
candidate sites in JEV that are involved in the attenuation of its
virulence (Nitayaphan et al., 1990; Aihara et al., 1991; Cecilia and
Gould, 1991; Hasegawa et al., 1992; Sumiyoshi et al., 1995; Chen et al.,
1996, Ni and Barrett, 1996; Ni and Barrett, 1998; Arroyo et al., 2001;
Wu et al., 2003; Lee et al., 2004; Chambers et al., 2007). However, only
two sites in the E protein, 138 and 279, have been shown to be
determinants of its viral pathogenicity (Sumiyoshi et al., 1995;
Monath et al., 2002; Zhao et al., 2005). In the present study, we
focused on the four sites – 123 (S123R), 129 (Met to Thr, M129T), 222
(Ser to Ala, S222A) and 227 (S227P) – in the E proteins. Our data
demonstrate that the novel candidate position 123 is one of the
molecular determinants of JEV virulence. The S123R mutation also
increased the growth rate of Mie/41/2002 in mouse neuroblastoma
N18 cells to the same level as observedwith Beijing-1. The results of in
vitro growth analysis in N18 cells were consistent with those of
virulence experiment in vivo, suggesting that the increased virulence
of the mutant Mie/41/2002 may attributed to increased growth
activity of the virus caused by the S123R mutation in nerve cells.
Previous report has indicated that virulence attenuation of JEV as a
result of altered afﬁnity for the cell surface glycosaminoglycan (GAG)
occurs through at least one or two mutations in the E protein,
suggesting that afﬁnity for GAG is a key determinant for the
pathogenicity of JEV (Lee et al., 2004). It is possible that the mutation
S123R changes the afﬁnity of the E protein for the surface molecule
that is speciﬁcally expressed on nerve cells and that is required for
attachment of JEV. On the basis of the crystallographic structure of the
E protein from Tick-borne encephalitis virus and West Nile virus, the
amino acid at position 123 is located in domain II, which is important
for homodimerization of the E proteins (Rey et al., 1995; Kolaskar and
Kulkarni-Kale, 1999; Nybakken et al., 2006). Single mutations
responsible for the virulence and cell tropism of ﬂaviviruses have
been mapped on the E protein, and the sites cluster in three distinct
regions: the distal face of domain III, the base of domain II, and the
contact between the domain I and III (Rey et al., 1995). Position 123 is
located in the second region. Amino acid substitutions in the second
region are thought to inﬂuence virulence by affecting the low pH
conformational transition, while mutations on the distal face of
domain III are considered to inﬂuence cell attachment of ﬂaviviruses
(Rey et al., 1995; Lee et al., 2004). These ﬁndings suggest the
possibility that the S123R mutation may alter the critical pH for the
conformational change followed by the fusion process between the E
protein and the endosomal membrane within the infected cells.
Alternatively, an attenuating mutation at position 138 of the JEV E
protein affects multiple steps of the viral life cycles and these changes
may induce substantial attenuation of JEV (Zhao et al., 2005).
Therefore, the mechanism for virulence enhancement by the S123R
mutation may not be a simple process. Mutations M129T and S222A
had no or weak effect on the growth properties in vitro and the
virulence in mice, which suggests that these mutations may not be
associated with the differences between Mie/41/2002 and Beijing-1.
In Vero cells, the S227P mutant grew slightly slower than its parentMie/41/2002, although the growth rates of the S123R, M129T, and
S222A mutants were similar to that of Mie/41/2002. The growth
kinetics of the S227P mutant in Vero cells was similar to those of the
intertypic viruses rJEV(EB1-M41) and rJEV(nEB1-M41). These data
suggest that one of the molecular determinants of efﬁcient growth in
Vero cells is the amino acid at position 227, whereas the major
determinant of growth in N18 cells is the one at position 123.
Interestingly, plaques induced by the S123R mutant were smaller
than those of Mie/41/2002 and the other three mutants, which
formed plaques of similar sizes in Vero cells. These observations imply
that the plaque size of JEV is not necessarily correlated with the
growth rate of the virus in Vero cells.
The Beijing-1 strain used in the study was obtained after 37
passages through suckling mouse brain and then 1 passage in Vero
cells. A comparison of the amino acid sequence of this Beijing-1 strain
and another Beijing-1 strain (GenBank accession L48961) (Hashimoto
et al., 1988) showed two different amino acids in the E protein
(positions 123 and 132), and the amino acid at position 123 of the
Beijing-1 (L48961) E protein was Ser, which is the same as in Mie/41/
2002. Alignment of the nucleotide sequences of JEV registered in the
GenBank revealed that JEV strains with an Arg at position 123 (R123)
in the E protein were the minority and that the great majority of JEV
strains had a Ser residues at this position (S123) (data not shown).
Flaviviruses usually exist as genetically heterogeneous populations
and a speciﬁc variant may be easily selected according to the cells
used for passage (Ni and Barrett, 1998; Wu et al., 2003; Chiou et al.,
2005). It is possible that the R123 strain is suitable for replication of
JEV in mouse nerve cells, and, therefore, had been selected for
passages in sucklingmouse brain. However, JEV strain GSS, which was
isolated from the brain of a JE patient in China has an Arg at position
123 in the E protein, suggesting that the R123 type of JEV might be
circulating in nature.
In the present study, we established a system for the production of
recombinant JEV. Full-length infectious clones of ﬂaviviruses have
been used as powerful tools for studying replication, pathogenesis,
and vaccine development. Several groups have already constructed
full-length infectious clones for JEV (Sumiyoshi et al., 1992; Zhang et
al., 2001;Mishin et al., 2001; Yun et al., 2003; Zeng et al., 2005; Zhao et
al., 2005; Chambers et al., 2007; Liang et al., 2009). All strains used for
the construction of the clones were genotype III JEV, whereas we used
genotype I JEV Mie/41/2002. The major genotype of JEV isolated in
Japan changed from genotype III to genotype I in the early 1990s (Ma
et al., 2003; Yoshida et al., 2005). It has also been reported that a
similar genotype shift occurred in Korea (Nam et al., 1996; Yang et al.,
2004), northern Vietnam (Nga et al., 2004) and Thailand (Nitatpat-
tana et al., 2008). In China, most JEV isolates were genotype III before
2001. However, in recent years, genotype I JEV has frequently been
isolated in some areas in China (Wang et al., 2007; Zhang et al., 2009).
These ﬁndings suggest that JEV genotype III has been replaced by
genotype I in East and Southeast Asia. Thus, the ﬁndings in the present
study are important for understanding the virulence of currently
circulating genotype I JEV. Our infectious clones will be useful for
studying growth properties and pathogenesis of genotype I JEV.
Materials and methods
Cell culture
Vero cells (9013 and NIBSC strains), porcine kidney PK15 cells and
mosquito C6/36 cells were cultured at 37 °C for Vero and PK15 and
28 °C for C6/36, in 5% CO2 in Eagle's minimum essential medium
(MEM) supplemented with 10% heat-inactivated fetal bovine serum
and 100 U penicillin–streptomycin/ml. Mouse neuroblastoma N18
cells were cultured at 37 °C in 5% CO2 in Dulbecco's modiﬁed Eagle
medium (DMEM) supplementedwith 10% fetal bovine serum and 100
U penicillin-streptomycin/ml.
Table 4
Primers used for construction of wild-type (Mie/41/2002) and mutant JEVcDNA clones.
Direction Primer Sequence (5′-3′)a
Forward (sense) JEV.NotI-T7 GATCGCGGCCGCTAATACGACTCACTATAGAGAAG
JEV.T7-5N TAATACGACTCACTATAGAGAAGTTTATCTGTGTGAACTTC
JEV.NotI-4665f GATCGCGGCCGCCACAGGAGTTTACCGAATCATG
JEV.6311f CACGCACAAACGCTATACTAG
JEV.8906f CTCTCGGAGCAGTGTTCGCTG
E123mF GGAAGAATGATCCAACCAGAG
E129mF CCAACCAGAGAACATCAAGTACG
E222mF TCCCTGGACGTCCCCCTCAAG
E227mF CGCCCCCCTCAAGCACGGCATG
Reverse (antisense) JEV.4786r TCATGATGGCTGCTCCTCTAG
JEV.7334r GTTCTTCTCTGAGCAGCTCTG
JEV.9418r GACCACTTTGTGCCTGTACG
JEV.BamHI-NsiI-3N GCTGGATCCATGCATAGATCCTGTGTTCTTCCTCAC
E123mR AAT GGC CTT CCT GGT ACA AGA
E129mR ATTGTTCTTCCAATGGCCTTCG
E222mR AGAGCAAGGTCATGGAACCATTC
E227mR TCCAGGGAAGAGAAAGGTCATGG
a T7 polymerase promoter sequences in JEV.NotI-T7 and JEV.T7-5N primers are shown in italic. Nucleotides that are different from those of original Mie/41/2002 are indicated
with underlines.
303S. Tajima et al. / Virology 396 (2010) 298–304Viruses
Mie/41/2002 (GenBank accession AB241119) was isolated in Mie
prefecture, Japan, in 2002 from swine serum and the virus was
propagated in Vero cells (Nerome et al., 2007). Beijing-1 (accession
AB510530) was obtained after 37 passages through suckling mouse
brain and then 1 passage in Vero cells (NIBSC).
Production of recombinant JEV
RNA from JEV Mie/41/2002 was extracted from the culture
supernatant ﬂuid by use of High Pure Viral RNA Kit (Roche
Diagnostics), and it was used for the synthesis of viral cDNA
using the SuperScript III Reverse Transcriptase (Invitrogen). Primers
used for construction of the recombinant clone are listed in Table 4.
The 5′ terminal-NS3 region of the JEV genome (region 1) was
ampliﬁed with primers JEV.T7-5N and JEV.4786r for the ﬁrst PCR
and primers JEV.NotI-T7 and JEV.4786r for the second PCR. The
primers JEV.T7-5N and JEV.NotI-T7 contain the complete T7
polymerase promoter sequence (TAATACGACTCACTATAG). The
NS2B-NS4B region of the JEV genome (region 2) was ampliﬁed
with the primers JEV.NotI-4665f and JEV.7334r. The NS3–NS5 region
of the JEV genome (region 3) was ampliﬁed with the primers
JEV.6311f and JEV.9418r, and the NS5-3′ terminal region of the JEV
genome (region 4) was ampliﬁed with the primers JEV.8906f and
JEV.BamHI-NsiI-3N. All PCR reactions were done using a thermo-
stable high-ﬁdelity DNA polymerase KOD-plus (Toyobo). The PCR
product of the region 2 was ﬁrst subcloned into the low-copy-
number plasmid pMW119 (Nippon Gene) at an EcoRI–KpnI site
(M41R2/pMW119) using competent-cell Stbl2 (Invitrogen). In this
process the EcoRI site in the pMW119 plasmid was disrupted. The
PCR fragment of the region 1 was subcloned into NotI–EcoRI site of
M41R2/pMW119 (M41R12/pMW119), and then the region 4
fragment was subcloned into KpnI–BamHI site of M41R12/
pMW119 (M41R124/pMW119). The complete JEV clone (rJEV
(Mie/41/2002)/pMW119) was constructed by insertion of the
region 3 into KpnI site of M41R124/pMW119. The nucleotide
sequence of the viral genome region of the recombinant clones
were checked after ampliﬁcation of the plasmids in Eschrichia coli.
To construct the molecular clones of the intertypic viruses rJEV
(EB1-M41), rJEV(nEB1-M41) and rJEV(cEB1-M41), the E region
(MluI-AgeI region), nE region (N-terminal side of E region) and cE
region (C-terminal side of E region), respectively, of rJEV(Mie/41/
2002)/pMW119 were replaced with the corresponding region of
Beijing-1(smb37v1).To construct four clones of missense mutant viruses rJEV
(E123B1-M41), rJEV(E129B1-M41), rJEV(E222B1-M41) and rJEV
(E227B1-M41), single-missense mutations (S123R, M129T, S222A
and S227P) were introduced into rJEV(Mie/41/2002)/pMW119 by
inverse PCR-based site-directed mutagenesis (Tajima et al., 2006) by
use of the following primer sets: E123mF and E123mR for S123R;
E129mF and E129mR for M129T; E222mF and E222mR for S222A;
and E227mF and E227mR for S227P (Table 4). The rJEV clones were
digested at the 3′ end of viral genome with NsiI, and the linearized
DNA was transcribed by using the mMASSAGE mMACHINE T7 kit
(Invitrogen). Recombinant viruses were recovered by transfection
with in vitro-transcribed RNA into Vero cells as described previously
(Tajima et al., 2006).
Analysis of growth kinetics and plaque size
For the growth kinetics analysis cells were plated into 6-well
culture plate (3×105 for Vero and 6×105 for N18 and C6/36 cells) and
infected with original and mutant JEVs at a multiplicity of infection of
0.1 (Vero cells) or 0.01 (N18 and C6/36 cells) plaque forming units
(PFU)/cell. Small aliquots of the media were recovered periodically,
and the titer of the aliquots was determined by a plaque assay on Vero
cells grown in 12-well culture plates. To evaluate the plaque size, Vero
and PK-15 cells (3×105) were plated in six-well plates and inoculated
with the viruses. Five days after inoculation, cells were ﬁxed with a
3.7% (v/v) formaldehyde solution in phosphate-buffer saline for 1 h,
then the methylcellulose overlay was removed and the cells were
stained with methylene blue solution for 2 h. The diameters of 15
plaques were measured and the mean plaque size in mm + standard
error was calculated. Differences in mean plaque sizes were analyzed
using Welch's t-test.
Mouse challenge
Female ddY mice (3 weeks old) were purchased from Japan SLC,
Inc. (Shizuoka, Japan). All mice were maintained in a speciﬁc-
pathogen-free environment. Groups of mice (n=10) were intraper-
itoneally inoculated with 1×104 PFU (100 μl) of recombinant virus
solution diluted with 0.9% NaCl solution. The mice were observed
for 3 weeks after inoculation to determine survival rates. All
experiments were conducted in accordance with the Fundamental
Rules for Animal Experiments of our institute. Survival curve
comparisons were performed using Prism software (GraphPad
software) statistical analysis that uses the log-rank (Mantel–Cox)
test.
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